Skip to tool information and report a problem
Rx

ChemoRx — Clinical Calculator

Oncology Pharmacist Verification Tool · Guideline-Informed Regimens

ChemoRx · Clinical Verification ⚠ Clinical use — verify independently
Patient Parameters
cm
kg
kg
⚠ BSA caps are institutional/protocol-specific — not a global standard. "No cap" is correct for most regimens unless your protocol or PI explicitly mandates one. Verify before applying.
Laboratory Values
Regimen Selection
Search by drug, regimen, or condition only — do not type patient names, MRNs, or dates of birth. This text is sent to a third-party AI service.
Dose Reduction (MD-Ordered)
% 0 = full dose
e.g. 20 = 20% dose reduction
Carboplatin AUC Override
Blank = use the regimen's protocol AUC.
Only affects Calvert-dosed (carboplatin) agents.
⚠ Cumulative Dose History
Anthracycline lifetime limit: 450–550 mg/m² (doxorubicin) · Bleomycin: ~400 units · Oxaliplatin neuropathy risk: >500 mg/m²
⬡

SELECT A REGIMEN AND ENTER PATIENT PARAMETERS

All calculations per pharmacist verification workflow

References
Calculation Methods & Dosing Formulas
  1. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-871. (BSA — DuBois formula, used for all BSA-based dosing)
  2. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756. (Calvert formula for carboplatin AUC dosing — original studies measured GFR by 51Cr-EDTA clearance; the current carboplatin PI presents this formula without specifying an estimation method, weight convention, or GFR cap)
  3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. (CrCl equation substituted for measured GFR in the Calvert formula by clinical convention, not by the carboplatin PI itself)
  4. Morrow A, Garland C, Yang F, et al. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review. J Oncol Pharm Pract. 2019;25(7):1651-1657. (Reviews the National Cancer Institute's 2010 recommendation to cap the Calvert-formula GFR/CrCl term at 125 mL/min, and the risk of overestimating AUC — i.e., overdosing — when actual body weight is substituted in obese patients for the Cockcroft-Gault calculation; this tool's actual/IBW/AdjBW weight-selection convention is deliberately retained for carboplatin dosing on this basis)
  5. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655. (Ideal body weight formula)
  6. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(18):2037-2048. (Actual-body-weight BSA dosing for cytotoxic chemotherapy in obesity)
  7. Hershman DL, Loprinzi C. Poorly understood aspects of chemotherapy dose limits: neutropenia, thrombocytopenia, and mucositis. ASCO Educational Book. — general dose-modification/lab-threshold convention referenced across regimens (ANC/platelet/hepatic dose-hold thresholds); verify each regimen's specific thresholds against its own current label.
Pivotal Clinical Trials (primary source for regimen dosing/scheduling)
  1. mFOLFOX6 (MOSAIC, OPTIMOX1) — de Gramont A et al. J Clin Oncol. 2000;18:2938-47
  2. FOLFIRI — Douillard JY et al. Lancet. 2000;355:1041-47
  3. FOLFIRINOX (ACCORD11) — Conroy T et al. N Engl J Med. 2011;364:1817-25
  4. R-CHOP (GELA LNH 98-5) — Coiffier B et al. N Engl J Med. 2002;346:235-42
  5. ABVD — Bonadonna G et al. Ann Intern Med. 1986;104:739-46
  6. AC (NSABP B-15) — Fisher B et al. J Clin Oncol. 1990;8:1483-96
  7. TC (US Oncology Research 9735) — Jones S et al. J Clin Oncol. 2006;24:5381-87
  8. BEP — Williams SD et al. N Engl J Med. 1987;316:1435-40
  9. HyperCVAD (MDACC protocol) — Kantarjian HM et al. J Clin Oncol. 2000;18:547-61
  10. EPOCH (DA-EPOCH-R) — Wilson WH et al. J Clin Oncol. 2012;30:3076-82
  11. FLOT (perioperative) (FLOT4-AIO) — Al-Batran SE et al. Lancet. 2019;393:1948-57
  12. TPF (TAX 323) — Vermorken JB et al. N Engl J Med. 2007;357:1695-704
  13. VRd (SWOG S0777) — Durie BGM et al. Lancet. 2017;389:519-27
  14. Dara-VRd (GRIFFIN / PERSEUS) — Voorhees PM et al. Blood. 2020;136:936-45; Sonneveld P et al. N Engl J Med. 2024;390:301-13
  15. KRd (ASPIRE) — Stewart AK et al. N Engl J Med. 2015;372:142-52
  16. R-ICE (US/NCI 21-day schedule) — NCI-2015-01990 / NCT02628405; Gisselbrecht C et al. J Clin Oncol. 2010;28:4184-90 (CORAL evidence base)
  17. R-DHAP — Velasquez WS et al. Blood. 1988;71:117-22
  18. THP (CLEOPATRA) — Swain SM et al. N Engl J Med. 2015;372:724-34
  19. T-DM1 (EMILIA / KATHERINE) — Verma S et al. N Engl J Med. 2012;367:1783-91; von Minckwitz G et al. N Engl J Med. 2019;380:617-28
  20. Carbo+Pacli+Bev (ovarian) (GOG-0218) — Burger RA et al. N Engl J Med. 2011;365:2473-83
  21. Pembro mono (KEYNOTE-001/010/024/158) — Various Merck trials
  22. Nivo+Ipi (NSCLC) (CheckMate 227/9LA) — Hellmann MD et al. N Engl J Med. 2019;381:2020-31
  23. Nivo+Ipi (Melanoma) (CheckMate 067) — Larkin J et al. N Engl J Med. 2015;373:23-34
  24. Pembro+Pem+Carbo (KEYNOTE-189) — Gandhi L et al. N Engl J Med. 2018;378:2078-92
  25. Pola-R-CHP (POLARIX) — Tilly H et al. N Engl J Med. 2022;386:351-63
  26. Sacituzumab (TNBC) (ASCENT) — Bardia A et al. N Engl J Med. 2021;384:1529-41
  27. T-DXd (breast) (DESTINY-Breast01/02/03/04) — Modi S et al. N Engl J Med. 2020;382:610-21
  28. BV-AVD (ECHELON-1) — Connors JM et al. N Engl J Med. 2018;378:331-44
  29. EV+Pembro (EV-302/KEYNOTE-A39) — Powles T et al. N Engl J Med. 2024;390:875-88
  30. Isa-VRd (GMMG-HD7 / IMROZ) — Goldschmidt H et al. Lancet. 2023;401:1035-46; Facon T et al. N Engl J Med. 2024;391:1597-609
  31. DRd (MAIA) — Facon T et al. N Engl J Med. 2019;380:2104-15
  32. Carbo+Etopo+Atezo (IMpower133) — Horn L et al. N Engl J Med. 2018;379:2220-29
  33. Atez+Carbo+Pacli+Bev (IMpower150) — Socinski MA et al. N Engl J Med. 2018;378:2288-301
  34. mFOLFOX6+Bev (NO16966 / TREE-2) — Saltz LB et al. J Clin Oncol. 2008;26:2013-19
  35. Nivo+mFOLFOX6 (gastric) (CheckMate 649) — Janjigian YY et al. Nature. 2021;596:579-90
  36. Pembro+Cis+5FU (gastric) (KEYNOTE-590/811) — Sun JM et al. Lancet. 2021;398:759-71
  37. Gem+NabPacli (pancreatic) (MPACT) — Von Hoff DD et al. N Engl J Med. 2013;369:1691-703
  38. GemCis (biliary) (ABC-02 / Valle trial) — Valle J et al. N Engl J Med. 2010;362:1273-81
  39. Atezo+Bev (HCC) (IMbrave150) — Finn RS et al. N Engl J Med. 2020;382:1894-905
  40. GemCis+Durva (biliary) (TOPAZ-1) — Oh DY et al. NEJM Evid. 2022;1:EVIDoa2200011
  41. Carbo+Pacli (gyn) (GOG-158 / ICON3) — Ozols RF et al. J Clin Oncol. 2003;21:3194-200
  42. Pembro+Carbo+Pacli (endometrial) (KEYNOTE-868/NRG-GY018) — Eskander RN et al. N Engl J Med. 2023;388:2159-70
  43. Dostarlimab+Carbo+Pacli (RUBY) — Mirza MR et al. N Engl J Med. 2023;388:2145-58
  44. Cabazitaxel (TROPIC) — de Bono JS et al. Lancet. 2010;376:1147-54
  45. Topotecan (SCLC 2L) — von Pawel J et al. J Clin Oncol. 1999;17:658-67
  46. Lurbinectedin (basket trial) — Trigo J et al. Lancet Oncol. 2020;21:645-54
  47. Kd (ENDEAVOR) — Dimopoulos MA et al. Lancet Oncol. 2016;17:27-38
  48. Nivo HNSCC (CheckMate 141) — Ferris RL et al. N Engl J Med. 2016;375:1856-67
  49. Tarlatamab (DeLLphi-301) — Ahn MJ et al. N Engl J Med. 2023;389:2063-75
  50. T-DXd+Pertuzumab (DESTINY-Breast09) — FDA approval December 2025
  51. Datopotamab deruxtecan (TROPION-Breast01 / TROPION-Lung05) — Bardia A et al. N Engl J Med. 2024;391:1104-15
  52. Enco+Cetux+mFOLFOX6 (BREAKWATER) — FDA accelerated approval Dec 2024; full approval Feb 2026
  53. Sotorasib+Panitumumab (CodeBreaK 300) — Fakih MG et al. N Engl J Med. 2023;389:2125-39
  54. Durvalumab+FLOT (MATTERHORN) — FDA approval November 2025
  55. Acalabrutinib+BR (ECHO) — FDA approval January 2025
  56. Acalabrutinib+Venetoclax (AMPLIFY) — FDA approval 2025
  57. Retifanlimab+Carbo+Pacli (anal) (POD1UM-303) — Rao S et al. N Engl J Med. 2024;391:318-29
  58. Dara-VCd (amyloidosis) (ANDROMEDA) — Kastritis E et al. N Engl J Med. 2021;385:46-58
  59. TCHP (neoadjuvant HER2+) (BERENICE / NeoSphere) — Swain SM et al. Ann Oncol. 2018;29:1396-1402
  60. HD-MTX (DLBCL CNS) — Glass B et al. J Clin Oncol. 2017;35:2041-48
  61. MVAC (bladder) — Sternberg CN et al. J Urol. 1988;139:461-69
  62. AI sarcoma (EORTC 62012) — Judson I et al. Lancet Oncol. 2014;15:415-23
  63. Docetaxel+Pred (prostate) (TAX 327) — Tannock IF et al. N Engl J Med. 2004;351:1502-12
  64. GemCis (lung/bladder) — Sandler AB et al. N Engl J Med. 2006;355:2542-50
  65. Olaparib (OLYMPIAD / SOLO-1/2) — Robson M et al. N Engl J Med. 2017;377:523-33
  66. Niraparib (PRIMA) — González-Martín A et al. N Engl J Med. 2019;381:2391-402
  67. Osimertinib (FLAURA) — Soria JC et al. N Engl J Med. 2018;378:113-25
  68. Durvalumab (PACIFIC) — Antonia SJ et al. N Engl J Med. 2017;377:1919-29
FDA Prescribing Information (primary source for agent-specific dosing, diluents, filters, stability)
Cytotoxic / chemotherapy agents:
Oxaliplatin (Eloxatin), Irinotecan (Camptosar), 5-Fluorouracil (Adrucil), Leucovorin, Capecitabine (Xeloda), Gemcitabine (Gemzar), Cisplatin (Platinol-AQ), Carboplatin (Paraplatin), Docetaxel (Taxotere), Paclitaxel (Taxol), Nab-Paclitaxel (Abraxane), Doxorubicin (Adriamycin), Cyclophosphamide (Cytoxan), Vincristine (Oncovin), Vinblastine (Velban), Bleomycin (Blenoxane), Dacarbazine (DTIC-Dome), Methotrexate, Etoposide (VePesid), Ifosfamide (Ifex), Cytarabine HD (Cytosar-U), Topotecan (Hycamtin), Cabazitaxel (Jevtana), Eribulin (Halaven), Bortezomib (Velcade).
Targeted agents & antibody-drug conjugates:
Trastuzumab (Herceptin), Pertuzumab (Perjeta), Ado-trastuzumab emtansine (Kadcyla), Fam-trastuzumab deruxtecan (Enhertu), Datopotamab deruxtecan (Datroway), Bevacizumab (Avastin), Cetuximab (Erbitux), Panitumumab (Vectibix), Rituximab (Rituxan), Polatuzumab vedotin (Polivy), Brentuximab vedotin (Adcetris), Enfortumab vedotin (Padcev), Sacituzumab govitecan (Trodelvy), Daratumumab (Darzalex / Faspro), Isatuximab (Sarclisa), Carfilzomib (Kyprolis), Pemetrexed (Alimta), Olaparib (Lynparza), Niraparib (Zejula), Osimertinib (Tagrisso), Encorafenib (Braftovi), Sotorasib (Lumakras), Venetoclax (Venclexta), Acalabrutinib (Calquence), Lurbinectedin (Zepzelca), Tarlatamab (Imdelltra).
Immunotherapy agents:
Pembrolizumab (Keytruda), Nivolumab (Opdivo), Ipilimumab (Yervoy), Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Dostarlimab (Jemperli), Retifanlimab (Zynyz).
All accessed via DailyMed and FDA Drugs@FDA. Verify against the current label before dispensing — labels change.
Safety & Administration Standards
This list covers the regimens/agents where a specific pivotal trial or FDA product could be identified for this bibliography. Some newer entries reference FDA approval dates directly (label not yet indexed) — verify against the current prescribing information regardless of citation type. Reconstructed from the tool's original development documentation; report any inaccuracy via the Feedback & Requests page.
Tool information, sources & feedback

Clinical review: A complete, dated review of this tool is not recorded here. An interface update does not certify its clinical content.

Population & limitations: Read the selected module’s eligibility, exclusions, and warnings alongside its result. Coverage differs by module; a result alone does not establish eligibility.

Open references · Clinical changes & source policy

Distinguish FDA labeling, guideline-supported practice, original validation studies, and institutional protocols when applying a recommendation. Source dates and limitations belong to each recommendation; no site-wide “verified” status is implied.

Report a clinical or interface problem · Interface release: site-2026-09-06. Reports include tool and release identifiers only; no patient inputs or results are attached.